This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Migraine and the combined oral contraceptive pill

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Patients should be warned to report increase in headache frequency or onset of focal symptoms - the combined pill should be discontinued and the patient urgently referred if focal neurological symptoms not typical of aura persist for 1 hour or more.

The combined pill is contra-indicated in:

  • patients who suffer regular severe migraines lasting more than 72 hours despite treatment
  • patients who suffer migraines with typical focal aura
  • in patients with migraines without aura if there more than one additional risk factor for arterial disease (1)
  • if migraine is treated with ergot derivatives

The combined pill can be prescribed with caution in patients who:

  • have migraines without typical focal aura

UKMEC Criteria state:

In consideration of UKMEC criteria and combined hormonal contraception (CHC):

 

Cardiovascular factors (including migraine) and UKMEC categories (3):

 

 

Check the summary of product characteristics before prescribing any combined oral contraceptive pill.

Reference:

  • (1) DTB (2000), 38 (1), 1-4.
  • (2) BNF 7.3
  • (3) FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2019)

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.